TVTX Travere Therapeutics, Inc.
Stock · NasdaqGM · United States · Healthcare · US89422G1076
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Travere Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
49.60 USD
+1.49%
52-week range
22.59 – 68.73
Dividend yield—
Market cap4.8B
NowoTrade score
29 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:37. Information, not advice.
Results
Next results
18 Feb 2027
in 103 days · 16:00 · estimate 0.84
Last results
-0.31 vs 0.42 estimated
02 Nov 2026 · Miss -174.3%
Beat the estimate
6 of 12
5 missed · 1 in line
Average surprise
+71.5%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 16:00 | 0.84 | — | — | Upcoming |
| 02 Nov 2026 16:00 | 0.42 | -0.31 | -174.3% | Miss |
| 04 Aug 2026 16:00 | 0.32 | -0.10 | -131.0% | Miss |
| 04 May 2026 16:00 | -0.06 | 0.05 | +187.0% | Beat |
| 19 Feb 2026 16:00 | 0.37 | 0.37 | -0.8% | In line |
| 30 Oct 2025 16:00 | -0.08 | 0.59 | +794.1% | Beat |
| 06 Aug 2025 16:00 | 0.04 | 0.13 | +225.0% | Beat |
| 01 May 2025 16:00 | -0.39 | -0.19 | +51.8% | Beat |
| 20 Feb 2025 16:00 | -0.38 | -0.47 | -24.2% | Miss |
| 31 Oct 2024 07:00 | -0.54 | -0.46 | +14.3% | Beat |
| 01 Aug 2024 16:00 | -0.72 | -0.65 | +9.2% | Beat |
| 06 May 2024 16:00 | -0.79 | -1.51 | -90.6% | Miss |
| 15 Feb 2024 16:00 | -0.92 | -0.94 | -2.1% | Miss |
| 07 Nov 2023 16:00 | 0.04 | 2.27 | +5,413.7% | Beat |
| 03 Aug 2023 16:00 | -0.93 | -0.77 | +17.0% | Beat |
| 04 May 2023 16:00 | -1.03 | -0.82 | +20.1% | Beat |
| 23 Feb 2023 16:00 | -0.84 | -0.76 | +9.3% | Beat |
| 27 Oct 2022 17:00 | -0.70 | -0.76 | -7.9% | Miss |
| 04 Aug 2022 07:00 | -0.70 | -0.65 | +6.9% | Beat |
| 05 May 2022 17:00 | -0.73 | -0.82 | -12.5% | Miss |
| 24 Feb 2022 16:00 | -0.50 | -0.61 | -22.1% | Miss |
| 28 Oct 2021 16:00 | -0.48 | -0.13 | +73.1% | Beat |
| 29 Jul 2021 16:00 | -0.50 | -0.39 | +22.0% | Beat |
| 06 May 2021 16:00 | -0.30 | -0.55 | -80.3% | Miss |
| 01 Mar 2021 16:00 | -0.21 | -2.20 | -928.0% | Miss |
| 05 Nov 2020 16:00 | -0.29 | -0.11 | +62.1% | Beat |
| 30 Jul 2020 16:00 | -0.36 | -0.22 | +38.9% | Beat |
| 11 May 2020 16:00 | -0.52 | -0.20 | +61.4% | Beat |
| 24 Feb 2020 16:00 | -0.37 | -0.26 | +29.3% | Beat |
| 30 Oct 2019 16:00 | -0.60 | -0.66 | -10.4% | Miss |
| 06 Aug 2019 16:00 | -0.40 | -0.58 | -45.9% | Miss |
| 07 May 2019 16:00 | -0.36 | -0.63 | -75.0% | Miss |
| 26 Feb 2019 16:00 | -0.27 | -0.21 | +21.5% | Beat |
| 01 Nov 2018 16:00 | -0.26 | -0.68 | -158.2% | Miss |
| 26 Jul 2018 16:00 | -0.11 | -0.25 | -127.3% | Miss |
| 01 May 2018 16:00 | -0.36 | -0.14 | +61.1% | Beat |
| 27 Feb 2018 16:00 | 0.13 | 0.07 | -46.2% | Miss |
| 07 Nov 2017 16:00 | -0.04 | 0.15 | +528.6% | Beat |
| 09 Aug 2017 16:00 | 0.03 | 0.03 | 0.0% | In line |
| 04 May 2017 16:00 | — | 0.01 | — | — |
| 01 Mar 2017 16:00 | 0.08 | — | -100.0% | — |
| 03 Nov 2016 16:00 | 0.06 | -0.09 | -250.0% | Miss |
| 04 Aug 2016 16:00 | 0.04 | 0.07 | +75.0% | Beat |
| 03 May 2016 16:00 | 0.06 | 0.14 | +141.1% | Beat |
| 25 Feb 2016 16:00 | -0.13 | -0.07 | +46.2% | Beat |
| 03 Nov 2015 16:00 | 1.39 | -0.04 | -102.9% | Miss |
| 04 Aug 2015 16:00 | 0.02 | 0.40 | +1,900.0% | Beat |
| 11 May 2015 16:00 | -0.18 | -0.04 | +77.8% | Beat |
| 14 May 2014 08:00 | -0.44 | -0.73 | -65.7% | Miss |
| 27 Mar 2014 09:00 | -0.30 | -0.76 | -153.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 490.7M | +110.5% | -25.5M | -5.2% | -0.29 | +92.9% | -20.4M |
| 2024 | 233.2M | +60.5% | -321.5M | -137.9% | -4.08 | -172.0% | -338.7M |
| 2023 | 145.2M | +32.7% | -111.4M | -76.7% | -1.50 | +65.7% | -321.6M |
| 2022 | 109.5M | — | -278.5M | -254.4% | -4.37 | — | -214.7M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 07 Apr 2022 | 28.69 | 29.35 | 27.17 | 28.84 | +0.87% | 898,600 | |
| 06 Apr 2022 | 28.08 | 29.09 | 28.00 | 28.59 | +0.95% | 1,256,000 | |
| 05 Apr 2022 | 28.90 | 29.49 | 28.11 | 28.32 | -2.34% | 990,800 | |
| 04 Apr 2022 | 27.80 | 29.13 | 27.43 | 29.00 | +4.17% | 934,600 | |
| 01 Apr 2022 | 25.79 | 27.98 | 25.59 | 27.84 | +8.03% | 1,074,900 | |
| 31 Mar 2022 | 25.74 | 26.14 | 25.37 | 25.77 | +2.63% | 555,600 | |
| 30 Mar 2022 | 25.76 | 26.27 | 24.98 | 25.11 | -3.61% | 374,500 | |
| 29 Mar 2022 | 24.68 | 26.16 | 24.26 | 26.05 | +5.59% | 537,000 | |
| 28 Mar 2022 | 25.58 | 25.61 | 23.86 | 24.67 | -2.22% | 420,500 | |
| 25 Mar 2022 | 24.88 | 25.72 | 24.70 | 25.23 | +0.16% | 520,800 | |
| 24 Mar 2022 | 24.93 | 25.37 | 24.61 | 25.19 | +2.07% | 822,300 | |
| 23 Mar 2022 | 25.08 | 25.66 | 24.57 | 24.68 | -2.57% | 817,100 | |
| 22 Mar 2022 | 24.26 | 25.59 | 24.12 | 25.33 | +2.84% | 630,300 | |
| 21 Mar 2022 | 24.78 | 25.59 | 24.50 | 24.63 | -1.99% | 673,800 | |
| 18 Mar 2022 | 24.32 | 25.33 | 24.30 | 25.13 | +1.91% | 1,135,900 | |
| 17 Mar 2022 | 23.98 | 24.80 | 23.76 | 24.66 | +1.61% | 473,900 | |
| 16 Mar 2022 | 24.23 | 24.32 | 23.33 | 24.27 | +1.51% | 540,900 | |
| 15 Mar 2022 | 24.03 | 24.12 | 23.36 | 23.91 | +0.59% | 776,300 | |
| 14 Mar 2022 | 24.21 | 24.77 | 23.47 | 23.77 | -1.00% | 949,300 | |
| 11 Mar 2022 | 25.79 | 25.99 | 23.99 | 24.01 | -5.55% | 530,000 | |
| 10 Mar 2022 | 25.20 | 25.77 | 24.53 | 25.42 | +1.19% | 1,232,300 | |
| 09 Mar 2022 | 23.40 | 25.12 | 23.08 | 25.12 | +6.40% | 4,126,700 | |
| 08 Mar 2022 | 24.00 | 25.39 | 22.16 | 23.61 | -11.47% | 4,739,900 | |
| 07 Mar 2022 | 25.96 | 27.12 | 25.96 | 26.67 | +1.37% | 292,800 | |
| 04 Mar 2022 | 26.50 | 27.18 | 26.08 | 26.31 | -1.46% | 336,000 |
Page 47 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67 (opens in a new tab) Benzinga · 05 Nov 2026 17:16
- Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72 (opens in a new tab) Benzinga · 04 Nov 2026 19:47
- Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78 (opens in a new tab) Benzinga · 04 Nov 2026 11:19
- Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why (opens in a new tab) Investor's Business Daily · 03 Nov 2026 21:36
- Travere Therapeutics to Participate at Upcoming Investor Conferences (opens in a new tab) 03 Nov 2026 21:30
- Travere Therapeutics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 13:30
- Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss (opens in a new tab) Simply Wall St. · 03 Nov 2026 08:10
- Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run (opens in a new tab) Simply Wall St. · 03 Nov 2026 07:06
- What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy? (opens in a new tab) Simply Wall St. · 03 Nov 2026 06:14
- Travere (TVTX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 04:59
- Travere: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 03 Nov 2026 04:37
- What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 03 Nov 2026 00:14
- Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 02 Nov 2026 23:58
- Travere Therapeutics (NASDAQ:TVTX) Revenue Beat Offset by Wider-Than-Expected Loss (opens in a new tab) ChartMill · 02 Nov 2026 23:41
- Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings (opens in a new tab) Zacks · 02 Nov 2026 22:30
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 48.87 USD
- Market cap
- 4.8B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 2.9 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Heavy debt: net debt is 4.5× EBITDA
- Thin interest cover: operating profit is only -5.8× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 9.4× | Good | 14.98× |
| Price / book | 210.17× | Weak | 3.94× |
| Price / sales | 7.31× | Weak | 3.37× |
| EV / EBITDA | 149.23× | Weak | 12.96× |
| Free cash flow yield | -1.4% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 61.1% | Good | 59.2% |
| Operating margin | 20% | Good | 7.4% |
| Net margin | -18.7% | Weak | 3.4% |
| Return on equity | -321.2% | Weak | 5.7% |
| Return on assets | -1.8% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 64.9% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 27.28× | Weak | 0.46× |
| Net debt / EBITDA | 4.45× | Weak | 1.5× |
| Interest cover | -5.85× | Weak | 3.26× |
| Current ratio | 3× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow TVTX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.